Skip to main content

Advertisement

Table 2 VARC-2 complications (30 days)

From: The association of diabetes mellitus treated with oral antidiabetic drugs and insulin with mortality after transcatheter valve implantation: a 3-year follow-up of the TAVIK registry

  Without diabetes (n = 1337) Diabetes on OAD (n = 387) Diabetes on insulin (n = 276) p-value HR (95% CI)* p-value*
Total mortality 68 (5.1) 17 (4.4) 21 (7.6) 0.255 1.05 (0.69–1.60) 0.814
 Cardiovascular death 45 (3.4) 15 (3.9) 15 (5.4) 0.212 0.91 (0.56–1.48) 0.711
 Noncardiovascular death 23 (1.7) 2 (0.5) 6 (2.2) 0.160 1.46 (0.64–3.36) 0.369
Myocardial infarction 14 (1.0) 7 (1.8) 4 (1.4) 0.379 0.58 (0.26–1.33) 0.201
Stroke 78 (5.8) 14 (3.6) 13 (4.7) 0.110 1.49 (0.94–2.35) 0.088
 Major/disabling stroke 29 (2.2) 8 (2.1) 8 (2.9) 0.731 0.94 (0.50–1.76) 0.854
 Minor stroke 49 (3.7) 6 (1.6) 5 (1.8) 0.046 2.19 (1.11–4.3) 0.023
Bleeding 254 (19.0) 71 (18.3) 58 (21.0) 0.809 0.96 (0.75–1.22) 0.735
 Life-threatening or major 127 (9.5) 33 (8.5) 31 (11.2) 0.936 1.02 (0.73–1.46) 0.927
 Minor 127 (9.5) 38 (9.8) 27 (9.8) 0.872 0.91 (0.66–1.26) 0.584
Renal complications 302 (22.6) 115 (29.7) 101 (36.6) < 0.001 1.46 (1.18–1.81) < 0.001
 Stage 2/3 36 (2.7) 13 (3.4) 13 (4.7) 0.170 0.73 (0.43–1.24) 0.248
Vascular complications 123 (9.2) 39 (10.1) 22 (8.0) 0.652 0.94 (0.67–1.31) 0.713
 Major 39 (2.9) 14 (3.6) 12 (4.3) 0.428 0.74 (0.44–1.24) 0.255
 Minor 84 (6.3) 25 (6.5) 10 (3.6) 0.211 1.09 (0.72–1.66) 0.676
New PPM implantation 175/1167 (15.0) 45/340 (13.2) 43/228 (18.9) 0.180 0.96 (0.72–1.27) 0.753
  1. VARC-2 criteria, Kappetein et al. [45]
  2. PPM primary pacemaker
  3. * Adjustment of significant basic parameters (age, ejection fraction, previous CABG, coronary artery disease, major neurological deficits, renal disease and frailty) between patients with and without DM